Weekly TP-HDFL in the Treatment of Advanced TCC

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of Weekly TP-HDFL in advanced transitional cell carcinoma in terms of response rate and overall survival.

Clinical Trial Description

Transitional cell carcinoma(TCC)of urothelium,including bladder, ureter, and renal pelvis TCCs, was the most lethal urology malignancy in Taiwan. In 1995, approximately 1,300 new cases of TCC was diagnosed in Taiwan and more than 600 patients died of this disease. Advanced TCC is a moderately chemosensitive disease. A combination of methotrexate, vinblastine, and cisplatin with or without doxorubicin (M-VAC or CMV) has been widely used since 1980s. Despite the response rate was as high as 40-70%, the survival of these patients was only slightly increased from a median of 7 to 9 months for those who were treated with supportive care or cisplatin alone to a median of 12 months by cisplatin-based combination chemotherapy. One of the reasons for the poor treatment results is the inevitable treatment-related toxicities related to conventional systemic chemotherapy. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00154687
Study type	Interventional
Source	National Taiwan University Hospital
Contact
Status	Completed
Phase	Phase 2
Start date	October 2000
Completion date	December 2004

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03296306` - Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma	Phase 3
Completed	`NCT00880334` - Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC	Phase 2
Completed	`NCT00216801` - Relationship of Ochratoxin A to Upper Urologic Cancers	N/A
Withdrawn	`NCT04179110` - Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor	Phase 2
Completed	`NCT00070070` - Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas	Phase 1
Completed	`NCT03256877` - Detecting Transitional Cell Carcinoma From Haematuria
Withdrawn	`NCT04006691` - Efficacy and Safety of UGN-101 in Recurrent Patients	Phase 3
Terminated	`NCT05052372` - Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Completed	`NCT00714025` - A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy	Phase 2
Terminated	`NCT01310803` - Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder	Phase 3
Completed	`NCT00623831` - A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen	Phase 1
Completed	`NCT00173862` - Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC	Phase 2
Recruiting	`NCT03896958` - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Terminated	`NCT01438112` - Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer	Phase 2/Phase 3
Completed	`NCT00683059` - Single Agent Abraxane as Second Line Therapy in Bladder Cancer	Phase 2
Recruiting	`NCT04811846` - CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood	N/A
Not yet recruiting	`NCT04878250` - Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder	Phase 2
Completed	`NCT00633789` - Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types	Phase 2
Completed	`NCT00612326` - Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging	N/A
Active, not recruiting	`NCT03219775` - Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma	Phase 2